| Emily Austin Haring, PA-C | |
|
890 Mountain Ave, New Providence, NJ 07974-1218 | |
| (908) 277-8770 | |
| (908) 673-7171 |
| Full Name | Emily Austin Haring |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 7 Years |
| Location | 890 Mountain Ave, New Providence, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184154601 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Saint Peter's University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Radiology Group Llc | 6608868500 | 213 |
News Archive
Merck recently has been providing lobbyists throughout the country with information about its human papillomavirus vaccine Gardasil in an effort to encourage states to mandate that middle-school age girls receive it, the Baltimore Sun reports.
Med-Vision, a Tampa-based medical consulting company providing strategies to lower healthcare costs and improve quality of care, is providing free healthcare planning advice and solutions via the Web. A newly launched Insights on Healthcare Blog (http://medvision.wordpress.com/) created by Dan Ross, president of Med-Vision, offers timely healthcare commentary, insights to help healthcare consumers, and information to help self-funded employers understand complicated issues of employee benefits.
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Secretary of State for Health, John Reid, reaffirmed the British Government's commitment to tackling health inequalities and congratulated all those who have been leading local action, at a national conference in London today.
The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced today the U.S. Food and Drug Administration has authorized the Investigational New Drug application for SKL15508 to treat cognitive impairment associated with schizophrenia.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Austin Haring, PA-C 11 Park Ave, Cranford, NJ 07016-1707 Ph: (631) 742-5879 | Emily Austin Haring, PA-C 890 Mountain Ave, New Providence, NJ 07974-1218 Ph: (908) 277-8770 |
News Archive
Merck recently has been providing lobbyists throughout the country with information about its human papillomavirus vaccine Gardasil in an effort to encourage states to mandate that middle-school age girls receive it, the Baltimore Sun reports.
Med-Vision, a Tampa-based medical consulting company providing strategies to lower healthcare costs and improve quality of care, is providing free healthcare planning advice and solutions via the Web. A newly launched Insights on Healthcare Blog (http://medvision.wordpress.com/) created by Dan Ross, president of Med-Vision, offers timely healthcare commentary, insights to help healthcare consumers, and information to help self-funded employers understand complicated issues of employee benefits.
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Secretary of State for Health, John Reid, reaffirmed the British Government's commitment to tackling health inequalities and congratulated all those who have been leading local action, at a national conference in London today.
The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced today the U.S. Food and Drug Administration has authorized the Investigational New Drug application for SKL15508 to treat cognitive impairment associated with schizophrenia.
› Verified 5 days ago
Zachary Vojt, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 550 Central Ave Ste 500, New Providence, NJ 07974 Phone: 908-795-1192 Fax: 908-795-1193 | |
Mr. Jeffrey Neil Emiliani, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1286 Springfield Ave, New Providence, NJ 07974 Phone: 908-402-3338 | |
Alina Godovska, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 550 Central Ave Ste 500, New Providence, NJ 07974 Phone: 908-779-5311 Fax: 908-522-5999 | |
Mr. Michael Francis Gerne, PHYSICIAN ASSISTANT Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 550 Central Ave Ste 500, New Providence, NJ 07974 Phone: 908-795-1192 Fax: 908-795-1193 |